You were redirected to http://www.grifols.com/en/agreements-between-shareholders .

Click the following link if you want to dismiss this redirect and access the original URL: Link .

Skip to Content

Q3’26 Earnings Results on November 2, 2026. at 5:35pm CET. Webcast scheduled at 6:30pm CET

Contact us
International Headquarters
Adverse reactions - Pharmacovigilance
Grifols Ethics Line

Change Language
Español
Deutsch
中文

Company

Since 1909, Grifols has worked to improve the health and well-being of people around the world.

Read more
- Corporate Structure
  
  Board of Directors
  
  Management Team
- What We Do
  
  Biopharma
  
  Diagnostic
  
  Grifols Bio Supplies
  
  Healthcare Solutions for Hospitals
- Grifology
  
  The Cabinet
- Grifols Engineering
Every action we take is motivated by our mission to improve people's lives.

Our unique and remarkable history combines scientiﬁc expertise with a desire to serve patients and society.

We develop, produce and market innovative medicines, solutions and services in more than 110 countries.
Innovation

Grifols is full speed ahead on developing the next innovative breakthroughs across multiple therapeutic areas.

Read more
- CHRONOS-PD: Plasma Science in Parkinson’s Research
- Extending Our Innovative Reach
  
  Team Up with Grifols Innovation and New Technologies
  
  Scientific Awards and Programs
- Connecting Knowledge - Our R&D Network
We apply our growing knowledge of plasma to change healthcare.

Our treatments are enhancing people’s well-being and quality of life.

We’re drawing on a broad scientific base to continue innovating.
Sustainability

Grifols' longstanding commitment to people and the planet entails helping society on all fronts.

Read more
- Social Commitment
  
  Supporting Patients
  
  Supporting Donors
  
  Our People
  
  Social Action
- Environmental Responsibility
- Ethical Leadership
- Sustainability Reports & Corporate Policies
2025 Integrated and Sustainability Annual Report

Innovating with purpose to drive positive impact
Products
Investors

Read more
- Stock Information
  
  Stock and share capital
  
  Dividends
  
  Major Holders and Treasury Stock
  
  Agreements between Shareholders
  
  Analyst Coverage
- Financials
  
  Financial Results
  
  Annual Accounts
  
  Fixed Income and Credit Ratings
  
  Average Period of Payment to Suppliers
  
  Key Figures
- Press Releases
- Presentations and Events
- Agenda
- Communications with CNMV and SEC
  
  CNMV
  
  SEC
  
  Other Relevant Information
  
  Inside Information
  
  Significant events until 8 February 2020
- Corporate Stewardship Reports
Presentation First-Half 2026 Results

2025 Integrated and Sustainability Annual Report
Careers

People are at the heart of our business. We are committed to continued investment in training and development.

Explore Opportunities
- Why Grifols
  
  People & Culture
  
  Our teams
Media

Latest news about the company and contact information for journalists and communication professionals.

Read more
- Newsroom
- Events
  
  H1 2026 Financial Results
  
  General Shareholders' Meeting 2026
- Media Contacts
- Media Center
Suppliers

At Grifols, we believe in long-term, mutually trusting relationships with our partners.

More details
- Join Grifols Supplier Network

Change Language
Español
Deutsch
中文

Company
Innovation
Sustainability
Products
Investors
Careers
Media
Suppliers
- Suppliers
- Join Grifols Supplier Network

Connect with us

Grifols Investors Stock Information Agreements between Shareholders

Agreements between Shareholders

There are no agreements between shareholders

Related Websites

Related Websites

Grifols Plasma
Grifols Diagnostics Solutions
Grifols Scientific Awards
Grifols Engineering
Victor Grifols i Lucas Foundation
Probitas Foundation
J.A. Grifols Foundation

Grifols Self-Sufficiency Programs

Grifols Self-Sufficiency Programs

Grifols Egypt for Plasma Derivatives
Grifols Canada

Legal & Help

Privacy Notices
Cookies Policy
Cookies Settings
Terms of Use
Grifols Ethics Line
Contact
Glossary

Connect with us

© 2026 Grifols, S.A. All rights reserved worldwide.